S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
Is This The End of Capitalism? (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
NASDAQ:AGRX

Agile Therapeutics - AGRX Stock Forecast, Price & News

$0.27
0.00 (0.00%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.27
$0.29
50-Day Range
$0.18
$0.31
52-Week Range
$0.18
$15.60
Volume
860,458 shs
Average Volume
1.02 million shs
Market Capitalization
$10.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Agile Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
1.44mentions of Agile Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.12) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

562nd out of 1,055 stocks

Pharmaceutical Preparations Industry

280th out of 518 stocks


AGRX stock logo

About Agile Therapeutics (NASDAQ:AGRX) Stock

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Maxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
AGRX Agile Therapeutics, Inc.
EQS-News: This Biotech Company is Pursuing Positive Cash Flow In 2023
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Company Calendar

Last Earnings
11/07/2022
Today
1/31/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

Net Income
$-74,890,000.00
Net Margins
-797.48%
Pretax Margin
-853.10%

Debt

Sales & Book Value

Annual Sales
$8.40 million
Book Value
$3.05 per share

Miscellaneous

Free Float
38,706,000
Market Cap
$10.94 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Al Altomari
    Chairman & Chief Executive Officer
  • Jason Butch
    Chief Accounting & Financial Officer, VP
  • Paul Korner
    Chief Medical Officer
  • Robert G. Conway
    Chief Supply Chain Officer & Senior Vice President
  • Geoffrey P. Gilmore
    Chief Administrative Officer













AGRX Stock - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings
or view top-rated stocks.

How have AGRX shares performed in 2023?

Agile Therapeutics' stock was trading at $0.2270 at the beginning of 2023. Since then, AGRX stock has increased by 18.7% and is now trading at $0.2694.
View the best growth stocks for 2023 here
.

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AGRX earnings forecast
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) posted its earnings results on Monday, November, 7th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.07. The specialty pharmaceutical company earned $3 million during the quarter, compared to analysts' expectations of $2.46 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 1,074.50% and a negative net margin of 797.48%.

When did Agile Therapeutics' stock split?

Shares of Agile Therapeutics reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics updated its FY 2023 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $20.26 million.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $0.27.

How much money does Agile Therapeutics make?

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $10.94 million and generates $8.40 million in revenue each year. The specialty pharmaceutical company earns $-74,890,000.00 in net income (profit) each year or ($15.02) on an earnings per share basis.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.

This page (NASDAQ:AGRX) was last updated on 1/31/2023 by MarketBeat.com Staff